Guidance Document: Tamper-resistance Formulations of Opioid Drug Products

Guidance Document: Tamper-resistance Formulations of Opioid Drug Products This guidance document is specific to the "tamper-resistance" feature of controlled-release opioid products. It is intended for the pre-market review of drug submissions when sponsors seek to obtain approval for controlled-release opioid drug formulations with tamper-resistant properties and wish to include, in product monographs, scientific statements and claims regarding tamper-resistance. 2021-07-07 Health Canada open-ouvert@tbs-sct.gc.ca Health and SafetyGuidance documenttamper-resistance formulationstamper-resistant propertiesopioid drug productscontrolled-release opioid drug formulationscontrolled-release opioid productsdrug submissionsproduct monographs Guidance Document: Tamper-resistance Formulations of Opioid Drug ProductsHTML https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/tamper-resistance-formulations-opioid-drug-products.html#a1 Guidance Document: Tamper-resistance Formulations of Opioid Drug ProductsHTML https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/lignes-directrices/proprietes-resistance-alteration-produits-pharmaceutiques-opioides.html#a1

This guidance document is specific to the "tamper-resistance" feature of controlled-release opioid products. It is intended for the pre-market review of drug submissions when sponsors seek to obtain approval for controlled-release opioid drug formulations with tamper-resistant properties and wish to include, in product monographs, scientific statements and claims regarding tamper-resistance.

Data and Resources

Similar records